{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:16:03Z","timestamp":1784740563993,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":48,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["WK9110000101"],"award-info":[{"award-number":["WK9110000101"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972006"],"award-info":[{"award-number":["81972006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platinum-based chemotherapy remains the first-line treatment for advanced lung squamous cell carcinoma (LUSC), but its efficacy is often hindered by the development of chemoresistance. Although long noncoding RNAs (lncRNAs) are recognized as regulators of tumor progression and drug resistance, the functional contribution of natural antisense transcripts (NATs), a major subclass of lncRNAs involved in cisplatin resistance in LUSC, remains poorly understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patient-derived xenograft (PDX) models of LUSC were established and treated with cisplatin to identify cisplatin-resistant and cisplatin-sensitive tumor tissues. LncRNA microarray profiling was used to identify transcripts associated with cisplatin resistance. The functional role of a candidate lncRNA, termed LPCRL (LUSC primary cisplatin resistance-associated LncRNA), was assessed in vitro via MTT, flow cytometry, colony formation, and Transwell migration assays. Its effects on tumor growth and metastasis were further validated in vivo. Mechanistic insights were gained through RNA pull-down, silver staining, RNA immunoprecipitation (RIP), coimmunoprecipitation (Co-IP), and Western blot analyses. Finally, the therapeutic potential of LPCRL-targeting siRNA was assessed in a LUSC PDX model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that LPCRL was significantly upregulated in primary cisplatin-resistant PDX tissues. Functionally, LPCRL promoted primary cisplatin resistance and enhanced the proliferation and migration of LUSC cells both in vitro and in vivo. Mechanistically, LPCRL functions as a molecular scaffold to facilitate the interaction between MIB1 and USP15. This complex enables USP15 to deubiquitinate MIB1, thereby increasing MIB1 stability and promoting its nuclear export. The subsequent cytoplasmic accumulation of MIB1 enhances the ubiquitination of DLL4, leading to Notch pathway activation and upregulation of the downstream effector HES1. Importantly, intratumoral administration of LPCRL-targeting siRNA in PDX models suppressed tumor growth and sensitized tumors to cisplatin in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study revealed that LPCRL promotes LUSC malignancy and cisplatin resistance via the USP15\/MIB1\/Notch axis, highlighting LPCRL as a promising therapeutic target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03721-7","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:15:58Z","timestamp":1777590958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel antisense lncRNA, LPCRL, functions as a molecular scaffold for the USP15\/MIB1 complex to promote primary cisplatin resistance and tumor progression in lung squamous cell carcinoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Peng","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoxin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuee","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baolong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"3721_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"3721_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ccell.2022.09.018","volume":"40","author":"SCM Lau","year":"2022","unstructured":"Lau SCM, Pan Y, Velcheti V, Wong KK. Squamous cell lung cancer: Current landscape and future therapeutic options. Cancer Cell. 2022;40(11):1279\u201393.","journal-title":"Cancer Cell"},{"issue":"10515","key":"3721_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1016\/S0140-6736(25)01848-3","volume":"406","author":"Z Chen","year":"2025","unstructured":"Chen Z, Yang F, Jiang Z, et al. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial. Lancet. 2025;406(10515):2078\u201388.","journal-title":"Lancet"},{"key":"3721_CR4","first-page":"111856","volume":"828","author":"H Umar","year":"2024","unstructured":"Umar H, Wahab HA, Attiq A, Amjad MW, Bukhari SNA, Ahmad W. Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC). Mutat Res. 2024;828:111856.","journal-title":"Mutat Res"},{"issue":"5","key":"3721_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","volume":"20","author":"DS Ettinger","year":"2022","unstructured":"Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(5):497\u2013530.","journal-title":"J Natl Compr Canc Netw"},{"key":"3721_CR6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1186\/s12885-015-1635-9","volume":"15","author":"H Salim","year":"2015","unstructured":"Salim H, Zong D, H\u00e5\u00e5g P, Novak M, M\u00f6rk B, Lewensohn R, et al. DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines. BMC Cancer. 2015;15:628.","journal-title":"BMC Cancer"},{"issue":"7","key":"3721_CR7","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1158\/1535-7163.MCT-15-0062","volume":"14","author":"LR Kong","year":"2015","unstructured":"Kong LR, Chua KN, Sim WJ, et al. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS\/MAPK Pathway Activation in Squamous Cell Carcinoma. Mol Cancer Ther. 2015;14(7):1750\u201360.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3721_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12943-025-02415-6","volume":"24","author":"A Bitaraf","year":"2025","unstructured":"Bitaraf A, Zafarani A, Jahandideh P, et al. MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy. Mol Cancer. 2025;24(1):245.","journal-title":"Mol Cancer"},{"issue":"12","key":"3721_CR9","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1016\/j.ymthe.2023.09.015","volume":"31","author":"YQ Ao","year":"2023","unstructured":"Ao YQ, Gao J, Jiang JH, Wang HK, Wang S, Ding JY. Comprehensive landscape and future perspective of long noncoding RNAs in non-small cell lung cancer: it takes a village. Mol Ther. 2023;31(12):3389\u2013413.","journal-title":"Mol Ther"},{"issue":"1","key":"3721_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13046-025-03462-z","volume":"44","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Shen Y, Che Y, et al. Hypoxia-inducible APCDD1L-AS1 promotes osimertinib resistance by stabilising DLST to drive tricarboxylic acid cycle in lung adenocarcinoma. J Exp Clin Cancer Res. 2025;44(1):197.","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"3721_CR11","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-23-3748","volume":"85","author":"T Qu","year":"2025","unstructured":"Qu T, Song L, Xu J, et al. MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer. Cancer Res. 2025;85(16):3052\u201371.","journal-title":"Cancer Res"},{"issue":"10","key":"3721_CR12","first-page":"730","volume":"25","author":"A Werner","year":"2024","unstructured":"Werner A, Kanhere A, Wahlestedt C, Mattick JS. Natural antisense transcripts as versatile regulators of gene expression. Nat Rev Genet. 2024;25(10):730\u201344.","journal-title":"Nat Rev Genet"},{"issue":"22","key":"3721_CR13","doi-asserted-by":"publisher","first-page":"22240","DOI":"10.1021\/acsnano.3c01199","volume":"17","author":"Y Gao","year":"2023","unstructured":"Gao Y, Tong M, Wong TL, et al. Long Noncoding RNA URB1-Antisense RNA 1 (AS1) Suppresses Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma by Driving Ferritin Phase Separation. ACS Nano. 2023;17(22):22240\u201358.","journal-title":"ACS Nano"},{"issue":"1","key":"3721_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41419-025-07931-3","volume":"16","author":"J Chen","year":"2025","unstructured":"Chen J, Fan C, Song S, Zhang D. LncRNA EP300-AS1 interacts with PTBP1 to destabilize PRMT5 mRNA and suppresses NSCLC growth and metastasis. Cell Death Dis. 2025;16(1):607.","journal-title":"Cell Death Dis"},{"issue":"31","key":"3721_CR15","doi-asserted-by":"publisher","first-page":"e05963","DOI":"10.1002\/advs.202505963","volume":"12","author":"Y Liu","year":"2025","unstructured":"Liu Y, Liu H, Zhu C, et al. Tumor Small Extracellular Vesicle-Transmitted LncRNA CATED Promotes Platinum-Resistance in High-Grade Serous Ovarian Cancer. Adv Sci (Weinh). 2025;12(31):e05963.","journal-title":"Adv Sci (Weinh)"},{"key":"3721_CR16","doi-asserted-by":"crossref","unstructured":"Wei X, Feng J, Chen L et al. METTL3-mediated m6A modification of LINC00520 confers glycolysis and chemoresistance in osteosarcoma via suppressing ubiquitination of ENO1. Cancer Lett. 2024; 217194.","DOI":"10.1016\/j.canlet.2024.217194"},{"issue":"1","key":"3721_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.ymthe.2021.06.006","volume":"30","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Guo H, Tong T, et al. lncRNA lnc-POP1-1 upregulated by VN1R5 promotes cisplatin resistance in head and neck squamous cell carcinoma through interaction with MCM5. Mol Ther. 2022;30(1):448\u201367.","journal-title":"Mol Ther"},{"issue":"1","key":"3721_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-022-02560-6","volume":"42","author":"X Tao","year":"2023","unstructured":"Tao X, Li Y, Fan S, et al. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275\/PROCA1\/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma. J Exp Clin Cancer Res. 2023;42(1):12.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3721_CR19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","volume":"8","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu W, Cai C, Zhang H, Shen H, Han Y. Patient-derived xenograft models in cancer therapy: technologies and applications. Signal Transduct Target Ther. 2023;8(1):160.","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"3721_CR20","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"3721_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13046-019-1079-1","volume":"38","author":"P Luo","year":"2019","unstructured":"Luo P, Wang Q, Ye Y, et al. MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop. J Exp Clin Cancer Res. 2019;38(1):74.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"3721_CR22","first-page":"8589","volume":"15","author":"D Lu","year":"2018","unstructured":"Lu D, Luo P, Zhang J, et al. Patient-derived tumor xenografts of lung squamous cell carcinoma alter long non-coding RNA profile but not responsiveness to cisplatin. Oncol Lett. 2018;15(6):8589\u2013603.","journal-title":"Oncol Lett"},{"issue":"3","key":"3721_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","volume":"181","author":"B Gy\u0151rffy","year":"2024","unstructured":"Gy\u0151rffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol. 2024;181(3):362\u201374.","journal-title":"Br J Pharmacol"},{"issue":"31","key":"3721_CR24","doi-asserted-by":"publisher","first-page":"e13256","DOI":"10.1002\/advs.202413256","volume":"12","author":"B Luo","year":"2025","unstructured":"Luo B, Luo Y, Chen S, et al. Real-Time Evolutionary Landscape of the Bronchial Epithelium and Corresponding Dynamic Immune Cell Alterations in Lung Squamous Cell Carcinogenesis. Adv Sci (Weinh). 2025;12(31):e13256.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"3721_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/jhg.2011.108","volume":"57","author":"SH Almal","year":"2012","unstructured":"Almal SH, Padh H. Implications of gene copy-number variation in health and diseases. J Hum Genet. 2012;57(1):6\u201313.","journal-title":"J Hum Genet"},{"issue":"2","key":"3721_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1158\/1541-7786.MCR-21-0342","volume":"20","author":"H Wang","year":"2022","unstructured":"Wang H, Huang Q, Xia J, et al. The E3 Ligase MIB1 Promotes Proteasomal Degradation of NRF2 and Sensitizes Lung Cancer Cells to Ferroptosis. Mol Cancer Res. 2022;20(2):253\u201364.","journal-title":"Mol Cancer Res"},{"key":"3721_CR27","doi-asserted-by":"publisher","first-page":"215976","DOI":"10.1016\/j.canlet.2022.215976","volume":"552","author":"W Zhang","year":"2023","unstructured":"Zhang W, Qian W, Gu J, et al. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Cancer Lett. 2023;552:215976.","journal-title":"Cancer Lett"},{"issue":"8","key":"3721_CR28","doi-asserted-by":"publisher","first-page":"e2206694120","DOI":"10.1073\/pnas.2206694120","volume":"120","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Lu YX, Liu F, et al. lncRNA BREA2 promotes metastasis by disrupting the WWP2-mediated ubiquitination of Notch1. Proc Natl Acad Sci U S A. 2023;120(8):e2206694120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3721_CR29","doi-asserted-by":"crossref","unstructured":"Wang H, Wu L, Liu C et al. A novel lncRNA, lncMCL1, modulates neural pyroptosis associated with epilepsy via stabilizing DDX3X. Cell Death Differ. Published online September 22, 2025.","DOI":"10.1038\/s41418-025-01584-7"},{"key":"3721_CR30","doi-asserted-by":"publisher","first-page":"101245","DOI":"10.1016\/j.drup.2025.101245","volume":"83","author":"Z Miao","year":"2025","unstructured":"Miao Z, Sha Z, He J, et al. Long non-coding RNA LRTOR drives osimertinib resistance in non-small cell lung cancer by boosting YAP positive feedback loop. Drug Resist Updat. 2025;83:101245.","journal-title":"Drug Resist Updat"},{"key":"3721_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.sbi.2016.05.012","volume":"41","author":"B Guo","year":"2016","unstructured":"Guo B, McMillan BJ, Blacklow SC. Structure and function of the Mind bomb E3 ligase in the context of Notch signal transduction. Curr Opin Struct Biol. 2016;41:38\u201345.","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"3721_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41419-025-07374-w","volume":"16","author":"X Deng","year":"2025","unstructured":"Deng X, Chang L, Tang L, et al. Long noncoding RNA GDIL acts as a scaffold for CHAC1 and XRN2 to promote platinum resistance of colorectal cancer through inhibition of glutathione degradation. Cell Death Dis. 2025;16(1):62.","journal-title":"Cell Death Dis"},{"issue":"6","key":"3721_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41388-023-02910-4","volume":"43","author":"X Yu","year":"2024","unstructured":"Yu X, Zhao P, Luo Q, et al. RUNX1-IT1 acts as a scaffold of STAT1 and NuRD complex to promote ROS-mediated NF-\u03baB activation and ovarian cancer progression. Oncogene. 2024;43(6):420\u201333.","journal-title":"Oncogene"},{"issue":"1","key":"3721_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-025-03368-w","volume":"44","author":"J Qi","year":"2025","unstructured":"Qi J, Jiang T, Liu B, et al. LINC02167 stabilizes KSR1 mRNA in an m5C-dependent manner to regulate the ERK\/MAPK signaling pathway and promotes colorectal cancer metastasis. J Exp Clin Cancer Res. 2025;44(1):121.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3721_CR35","doi-asserted-by":"publisher","first-page":"12471","DOI":"10.1038\/s41598-019-48902-x","volume":"9","author":"SE Dho","year":"2019","unstructured":"Dho SE, Silva-Gagliardi N, Morgese F, et al. Proximity interactions of the ubiquitin ligase Mind bomb 1 reveal a role in regulation of epithelial polarity complex proteins. Sci Rep. 2019;9(1):12471.","journal-title":"Sci Rep"},{"issue":"6","key":"3721_CR36","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/j.celrep.2019.04.036","volume":"27","author":"T Douanne","year":"2019","unstructured":"Douanne T, Andr\u00e9-Gr\u00e9goire G, Thys A, Trillet K, Gavard J, Bid\u00e8re N. CYLD Regulates Centriolar Satellites Proteostasis by Counteracting the E3 Ligase MIB1. Cell Rep. 2019;27(6):1657\u201365.","journal-title":"Cell Rep"},{"issue":"6","key":"3721_CR37","doi-asserted-by":"publisher","first-page":"eabe3706","DOI":"10.1126\/sciadv.abe3706","volume":"7","author":"U Majumdar","year":"2021","unstructured":"Majumdar U, Manivannan S, Basu M, et al. Nitric oxide prevents aortic valve calcification by S-nitrosylation of USP9X to activate NOTCH signaling. Sci Adv. 2021;7(6):eabe3706.","journal-title":"Sci Adv"},{"issue":"1","key":"3721_CR38","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41420-022-00820-0","volume":"8","author":"T Das","year":"2022","unstructured":"Das T, Lee EY, You HJ, Kim EE, Song EJ. USP15 and USP4 facilitate lung cancer cell proliferation by regulating the alternative splicing of SRSF1. Cell Death Discov. 2022;8(1):24.","journal-title":"Cell Death Discov"},{"key":"3721_CR39","doi-asserted-by":"publisher","first-page":"216647","DOI":"10.1016\/j.canlet.2024.216647","volume":"585","author":"J Sun","year":"2024","unstructured":"Sun J, Dong M, Xiang X, Zhang S, Wen D. Notch signaling and targeted therapy in non-small cell lung cancer. Cancer Lett. 2024;585:216647.","journal-title":"Cancer Lett"},{"issue":"1","key":"3721_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024;9(1):128.","journal-title":"Signal Transduct Target Ther"},{"key":"3721_CR41","doi-asserted-by":"publisher","first-page":"1585624","DOI":"10.3389\/fimmu.2025.1585624","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhang Q, Guo C, et al. Hes1 in malignant tumors: from molecular mechanism to therapeutic potential. Front Immunol. 2025;16:1585624.","journal-title":"Front Immunol"},{"issue":"1","key":"3721_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41568-020-00308-y","volume":"21","author":"S Rottenberg","year":"2021","unstructured":"Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3721_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/bjc.2011.462","volume":"106","author":"S Kojima","year":"2012","unstructured":"Kojima S, Chiyomaru T, Kawakami K, et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012;106(2):405\u201313.","journal-title":"Br J Cancer"},{"issue":"6","key":"3721_CR44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ejca.2011.06.030","volume":"48","author":"K Kawakami","year":"2012","unstructured":"Kawakami K, Enokida H, Chiyomaru T, et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer. 2012;48(6):827\u201336.","journal-title":"Eur J Cancer"},{"key":"3721_CR45","doi-asserted-by":"publisher","first-page":"681867","DOI":"10.3389\/fgene.2021.681867","volume":"12","author":"C Zhao","year":"2021","unstructured":"Zhao C, Wang Y, Tu F, et al. A Prognostic Autophagy-Related Long Non-coding RNA (ARlncRNA) Signature in Acute Myeloid Leukemia (AML). Front Genet. 2021;12:681867.","journal-title":"Front Genet"},{"issue":"7214","key":"3721_CR46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nature07290","volume":"455","author":"MS Song","year":"2008","unstructured":"Song MS, Salmena L, Carracedo A, et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature. 2008;455(7214):813\u20137.","journal-title":"Nature"},{"issue":"8","key":"3721_CR47","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.tips.2025.06.007","volume":"46","author":"H Watmuff","year":"2025","unstructured":"Watmuff H, Crawford A, Eusse B, Jones AN. Structure-function-guided drug development efforts to target lncRNAs. Trends Pharmacol Sci. 2025;46(8):703\u201321.","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"3721_CR48","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1021\/acsnano.4c15130","volume":"19","author":"S Dong","year":"2025","unstructured":"Dong S, Fang H, Zhu J, et al. Inhalable siRNA Targeting IL-11 Nanoparticles Significantly Inhibit Bleomycin-Induced Pulmonary Fibrosis. ACS Nano. 2025;19(2):2742\u201358.","journal-title":"ACS Nano"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03721-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03721-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03721-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T04:21:44Z","timestamp":1781756504000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03721-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3721"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03721-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8106822\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the mouse experiments in this study were approved by the Institutional Animal Care and Use Committee of the University of Science and Technology of China (Approval No. 2019-N(A)-179). The collection of human samples and research were approved by the Ethics Committee of the University of Science and Technology of China (Approval No. 2019-N(H)-128), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}